HM Government

Could we create a world without dementia in the near future?

This is the question that for years no one has dared to ask. We assumed – wrongly – that dementia was just part of the ageing process instead of the disease of the brain it actually is. But 4 years ago that changed. The UK hosted the first ever G8 dementia summit, which set the explicit ambition to find a cure or disease-modifying therapy for dementia by 2025.

Since then, governments have formally united in the fight against dementia, and adopted the first Global Action Plan on Dementia, during the World Health Assembly in May 2017.

In the UK we have done much to improve diagnosis rates, from one of the lowest to one of the highest in Europe. This matters because an early diagnosis can support patients to make lifestyle changes that slow the progress of the disease – and also help families make adjustments to make their dementia journey easier.

Public attitudes – and specifically the stigma around dementia – are also changing. We now have over 2 million Dementia Friends, and the first dementia-friendly communities – both of them signalling a sea-change in the compassion with which we approach the disease.

And the establishment of the UK Dementia Research Institute earlier this year will provide a new focal point for research across care, prevention and technology as well as biomedical science.

We can’t do this alone. Our partnership with Japan, who pioneered Dementia Friends and like us faces many challenges with an ageing population, shows how valuable cross-border collaboration is when it comes to answering one of the biggest global health challenges of our times. We have been able to ensure a continued focus on dementia throughout Japan’s presidency of the G7, with learning exchanges between both nations, a successful global symposium on Building A Dementia Friendly World, and the establishment of Global Dementia Friends Ambassadors Carey Mulligan and Yuichiro Miura.

Message from Japan’s Dementia Supporters Ambassador, Mr Yuichiro Miura:

Yuichiro Miura.

But partnership needs to be not just between governments but with civil society and voluntary organisations as well. So we strongly support the brilliant work done by the Alzheimer’s Society, Alzheimer’s Research UK and other dementia-focused charities in the UK. And during the 2014 World Health Assembly, I was pleased to launch the Global Alzheimer’s and Dementia Action Alliance, encouraging international NGOs to join global action against this condition.

In the end, though, our approach to dementia is quite simply a litmus test of how compassionate a society we want to be. Living with dementia can be horrific for the individual and their family – but it doesn’t have to be. Social interaction – the love and support of family and friends – is one of the best possible ways to slow progression. We may not yet be able to cure the disease but we can all play a part in tackling the symptoms.

The Financial Conduct Authority (FCA) announced its decision to refer to the Competition and Markets Authority (CMA) for an in-depth market investigation on 14 September 2017.

As set out in the FCA’s terms of reference, the investigation covers investment consultancy services, which provide advice to institutional investors (mainly pension funds) and employers on their pension schemes; and fiduciary management services, where the provider makes and implements decisions for the investor (for example, to select a fund in which to invest).

The CMA is now carrying out a thorough and independent investigation to see if there are any market features which prevent, restrict or distort competition. If it does find competition concerns, the CMA will decide whether and – if so – what action is needed to resolve them.

The issues statement sets out a structure for the investigation, outlining potential issues and possible remedies to put in place if competition problems are found. We have grouped these in the following areas:

• whether difficulties in customers’ ability to assess, compare and switch investment consultants mean investment consultants have little incentive to compete for customers
• whether conflicts of interest on the part of investment consultants reduce the quality and/or value for money of services provided to customers
• whether barriers to entry and expansion mean there are fewer challengers to put pressure on the established investment consultants to be competitive – which leads to worse outcomes for customers

The above are matters that we will be testing in our investigation. The purpose of the issues statement is to help those submitting evidence to the CMA to focus on the issues that we will investigate. We will welcome views on whether the correct issues have been identified to date and whether other issues should also be investigated, as well as views on potential remedies.

The CMA has appointed an investigation group, which will act as the decision maker in the case. This will be chaired by John Wotton, one of the CMA’s designated inquiry chairs. The other panel members are Lesley Ainsworth, Bob Spedding and Tim Tutton. All the appointees are chosen from the CMA’s expert independent panel members, who come from a variety of backgrounds, including economics, law, accountancy and business.

John Wotton, Chair of the Investigation Group, said:

It is extremely important that the investment consultancy sector works effectively for its clients, which include many of the UK’s biggest pension funds, and we want to ensure we are looking at the right issues. That is why we are urging people to get in touch if they have any evidence to share or views about whether these are the correct areas for us to be investigating.

All information relating to the investigation will be available on the case page. Submissions in response to the issues statement are invited in writing by Thursday 12 October 2017 either by email to investmentconsultants@cma.gsi.gov.uk or to:

Notes for editors

1. The CMA is the UK’s primary competition and consumer authority. It is an independent non-ministerial government department with responsibility for carrying out investigations into mergers, markets and the regulated industries and enforcing competition and consumer law. It has functions under the Enterprise Act 2002, as amended by the Enterprise and Regulatory Reform Act 2013.

2. In its investigation, the CMA is required to decide whether ‘any feature, or combination of features, of each relevant market prevents, restricts or distorts competition in connection with the supply or acquisition of any goods or services in the United Kingdom or a part of the United Kingdom’. If so, then there is an ‘adverse effect on competition’ and the CMA will also consider whether there is a resulting detrimental effect on customers such as higher prices, lower quality or less choice of goods or services. The CMA will then decide whether it should put in place remedies (or recommend that other bodies should do so) to tackle the adverse effect on competition or any detrimental effect on customers so far as it has resulted from, or may be expected to result from, that adverse effect on competition, and if so, what action should be taken. If the CMA finds that there is no ‘adverse effect on competition’, the question of remedies will not arise.

3. Enquiries should be directed to the press@cma.gsi.gov.uk, on 020 3738 6191.

4. For more information see the CMA’s homepage, or follow us on Twitter @CMAgovuk, Flickr and LinkedIn. Sign up to our email alerts to receive updates on the markets cases.

Summary At around 21:30 hrs on 6 February 2017, at Bank Station on the Docklands Light Railway, part of a coat worn by a passenger on the platform became trapped in the closing door of a train. The passenger was unable to release her coat from the clo… read more

This short survey is being run via YouGov to gather more detailed feedback from suppliers on the issues of forecasting, promotions and delay in payments. This can be completed anonymously if you wish, and all information received will be treated in co… read more

We are exploring different ways and times in which you can contact us. At present our helplines are open Monday to Friday from 9am to 5pm. The survey will help us to find out if providers would like us to extend these hours or find other ways of commu… read more